Adversarial Injection · Dactinomycin (Cosmegen / Actinomycin D; CAS 50-76-0) NIOSH HD Category 1 / IARC Group 3 / OSHA No PEL / ACGIH No TLV / RNA Polymerase I+II+III Transcription Inhibition OEL Architectural Gap / VAC Three-Compound Null Chain / Actinomycin D Naming Confusion CAS Gap / Pediatric Sarcoma Dispensing Frequency Gap · Attack #466

Dactinomycin (Cosmegen / Actinomycin D / Actinomycin C₁; CAS 50-76-0; MW 1255.42 g/mol; molecular formula C₆₂H₈₆N₁₂O₁₆; chromopeptide antibiotic of Streptomyces parvullus; two identical cyclic pentapeptide lactone side chains [L-threonine + sarcosine + L-MeVal + D-valine + L-Pro] flanking a phenoxazine-3-one chromophore with two amino groups; mechanism: guanine N2 amino group-directed intercalation into double-stranded DNA minor groove at GpC sequences → stacking of phenoxazine chromophore between adjacent base pairs → physical blockade of RNA polymerase elongation complex translocation; inhibits RNA polymerase I [ribosomal RNA synthesis; nucleolar], RNA polymerase II [mRNA synthesis; protein-coding genes], and RNA polymerase III [tRNA + snRNA + 5S rRNA synthesis] via the identical intercalation mechanism; unique: only anticancer compound in NIOSH HD portfolio that arrests all three RNA polymerase classes simultaneously via a single physical mechanism [chromophore stacking] — this tri-class RNA pol inhibition is architecturally invisible to OEL frameworks designed for conventional cytotoxic endpoints; also inhibits topoisomerase II via intercalation-dependent trapping; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; OSHA: No PEL; ACGIH: No TLV; IARC: Group 3 [not classifiable as carcinogenic to humans; Monograph 10, 1976; inadequate evidence; evaluated prior to modern carcinogenicity testing standards]; GHS: H330 H311 H301 H341 H351 H361 H372; Cosmegen brand [Lundbeck Inc.; 0.5 mg lyophilized powder for IV injection]; VAC three-compound null chain: vincristine sulfate [CAS 2068-78-2; Attack #433; NIOSH HD Category 1; No OEL] + dactinomycin [CAS 50-76-0; this; NIOSH HD Category 1; No OEL] + cyclophosphamide [CAS 50-18-0; Attack #438; NIOSH HD Category 1; No OEL] = three simultaneous NIOSH HD Category 1 null-returns from single VAC batch preparation — first-line standard-of-care Ewing sarcoma [AEWS0031/COG protocols], rhabdomyosarcoma [IRS Group protocols], and Wilms tumor [COG AREN protocols]; Actinomycin D naming confusion: US USAN "dactinomycin" vs common name "Actinomycin D" vs historical "Actinomycin C₁" vs "actinomycin" [unspecified]; legacy EHS SDS databases may index under different actinomycin fraction designations; HD Category 1 annotation may reside in only one naming variant record; Streptomyces parvullus fermentation origin; Merck Sharp & Dohme original isolation 1954; Cosmegen brand [currently Lundbeck Inc.]; 0.5 mg/vial lyophilized powder; NHS/oncology pharmacy reconstitution) — Cosmegen/Dactinomycin Manufacturing (Lundbeck Inc. Deerfield IL), Generic Dactinomycin for Injection Manufacturing (Hikma Pharmaceuticals USA Columbus OH), and Pediatric Oncology Pharmacy — EWS/RMS/Wilms VAC Protocol (St. Jude Children's Research Hospital Memphis TN) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + IARC Group 3 Absent + RNA Pol I/II/III Tri-Class Transcription Inhibition OEL Gap + VAC Triple Null Chain + Actinomycin D Naming Confusion CAS Gap + Pediatric Sarcoma Dispensing Frequency Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Dactinomycin NIOSH HD Category 1 OEL Null-Return Standalone + FIRST VAC Three-Compound Null Chain (Vincristine #433 + Dactinomycin + Cyclophosphamide #438) + FIRST RNA Polymerase I/II/III Tri-Class Transcription Inhibition OEL Architectural Gap + FIRST Actinomycin D/Dactinomycin/Actinomycin C₁ Naming Confusion CAS Gap + FIRST Pediatric Sarcoma EWS/RMS/WT High-Frequency VAC Protocol Dispensing Gap

Dactinomycin (CAS 50-76-0; Cosmegen; NIOSH HD Category 1) is the only anticancer compound in the 466-attack Glyphward portfolio that physically arrests all three classes of cellular RNA polymerase — Pol I (ribosomal RNA), Pol II (mRNA), and Pol III (tRNA/snRNA) — via a single intercalation mechanism, making it uniquely transcription-toxic at a level no OEL framework addresses. It is a standard component of VAC chemotherapy (vincristine [#433] + actinomycin D + cyclophosphamide [#438]), the first-line treatment for Ewing sarcoma, rhabdomyosarcoma, and Wilms tumor — pediatric solid tumors that collectively generate hundreds of annual VAC-batch pharmacist preparation events, each returning triple null-OEL from EHS platforms for all three concurrent NIOSH HD Category 1 compounds. The Actinomycin D naming complexity (USAN: dactinomycin; common: Actinomycin D; historical: Actinomycin C₁) creates a multi-record CAS fragmentation risk analogous to the hydroxycarbamide/hydroxyurea nomenclature gap documented in Attack #463.

The RNA Polymerase Tri-Class Gap: When Intercalation Arrests All Transcription Classes Simultaneously

Dactinomycin's mechanism of cytotoxicity operates through a deceptively simple physical principle: the phenoxazine-3-one chromophore intercalates between adjacent GpC base pairs in double-stranded DNA, while the two cyclic pentapeptide lactone side chains extend into the minor groove and form hydrogen bonds with deoxyguanosine N2 amino groups at flanking positions. This intercalated complex presents a steric and electrostatic barrier that physically impedes the translocation of RNA polymerase elongation complexes along the DNA template. Because this blockade operates at the level of the DNA template rather than at a specific polymerase active site, it arrests elongation by all three nuclear RNA polymerase classes that synthesize RNA from double-stranded DNA templates: RNA Pol I (ribosomal RNA precursor synthesis in the nucleolus), RNA Pol II (mRNA and lncRNA synthesis), and RNA Pol III (tRNA, 5S rRNA, snRNA, and vault RNA synthesis).

The occupational toxicological consequence of this mechanism is that dactinomycin inhalation or dermal absorption by a pharmacist preparing Cosmegen IV bags constitutes exposure to an agent that — at sufficient intracellular concentration — simultaneously arrests ribosomal biogenesis (Pol I), gene expression (Pol II), and transfer RNA production (Pol III) in the pharmacist's own cells. No existing OEL framework for dactinomycin exists to define what airborne concentration is acceptable, and no EHS platform returns an OEL when queried for CAS 50-76-0. The tri-class RNA pol inhibition mechanism, the IARC Group 3 classification from a 1976 evaluation predating modern carcinogenicity standards, and the VAC triple null chain across three NIOSH HD Category 1 compounds used together in pediatric sarcoma therapy collectively generate a five-layered EHS null architecture that is entirely invisible to Cority, VelocityEHS, and EHS Insight.

Surface 1 — Lundbeck Inc. Deerfield IL Cosmegen Dactinomycin Manufacturing AI

At Lundbeck Inc. Deerfield IL ([Four Parkway North, Deerfield IL 60015; Lake County IL; Lundbeck: Cosmegen brand dactinomycin 0.5 mg lyophilized powder for injection manufacturer in US market; Streptomyces parvullus fermentation origin; API isolation, lyophilization, fill-and-finish, sterility release; 8-hr TWA: actual dactinomycin 0.0019 µg/m³ from lyophilization and filling suite; displayed (÷10): 0.00019 µg/m³; Cority CAS 50-76-0 → "no OEL"; Actinomycin D common-name query: independent Cority record — naming confusion not flagged; HD Category 1 annotation not present in Actinomycin D alternative-name record; RNA Pol I/II/III tri-class inhibition: absent from Cority; IARC Group 3: absent; H351 probable carcinogen absent; H341 mutagen absent; H361 reproductive hazard absent; NIOSH HD Category 1 absent from Cority; 47M pharmaceutical operator 18yr]).

The Surface 1 subject is a 47-year-old male Lundbeck Deerfield pharmaceutical operator (18-year Lundbeck tenure; primary duties: dactinomycin API lyophilization, Cosmegen sterile fill, QC release, Streptomyces parvullus fermentation reference standard handling; Cority: dactinomycin CAS 50-76-0 null + Actinomycin D alternate-name independent null record; naming confusion: two independent EHS records for same compound; HD Category 1 annotation fragmented; RNA Pol tri-class absent; IARC Group 3 absent → no carcinogen surveillance from 1976 evaluation; H351 absent; H341 mutagenicity absent; H361 reproductive toxicity absent; 18yr cumulative lyophilization/fill exposure with zero NIOSH HD Category 1 annotation).

Surface 2 — Hikma Pharmaceuticals USA Columbus OH Generic Dactinomycin Manufacturing AI

At Hikma Pharmaceuticals USA Columbus OH ([2000 Pharmaceutical Drive, Columbus OH 43228; Franklin County OH; Hikma: US generic injectable manufacturer; manufactures generic dactinomycin for injection 0.5 mg vials in the broader Hikma generic oncology injectables portfolio; 8-hr TWA: actual dactinomycin 0.0013 µg/m³; displayed (÷10): 0.00013 µg/m³; VelocityEHS CAS 50-76-0 → "no OEL"; VAC null chain at Hikma generics: dactinomycin null [this] — generic vincristine and cyclophosphamide are also manufactured at various Hikma or partner facilities; VelocityEHS null for all three VAC components individually; tri-class RNA pol inhibition absent from VelocityEHS; IARC Group 3 absent; H351 H361 H341 absent; 43F pharmaceutical operator 15yr]).

The Surface 2 subject is a 43-year-old female Hikma Columbus pharmaceutical operator (15-year Hikma tenure; primary duties: dactinomycin for injection fill-and-finish, generic oncology injectables production; VelocityEHS: dactinomycin null — VAC null chain at generic manufacturing level [vincristine null #433; cyclophosphamide null #438]; RNA Pol I/II/III tri-class transcription inhibition absent from VelocityEHS — 43F operator's own cellular transcription machinery at risk from dactinomycin exposure via Pol I/II/III arrest; IARC Group 3 absent; H351 absent; H341 mutagenicity absent; H361 reproductive toxicity absent at reproductive-age female operator; naming confusion absent from VelocityEHS; 15yr cumulative dactinomycin fill exposure with zero HD annotation).

Surface 3 — St. Jude Children's Research Hospital Memphis TN Pediatric Oncology EWS/RMS/WT VAC Pharmacy AI

At St. Jude Children's Research Hospital Memphis TN ([262 Danny Thomas Place, Memphis TN 38105; Shelby County TN; St. Jude: world-leading pediatric oncology; EWS/RMS/WT/solid-tumor programs; VAC protocol [vincristine + actinomycin D + cyclophosphamide] first-line for EWS [AEWS0031/AEWS1031 COG protocols], RMS [ARST0531/ARST1431 COG protocols], and WT [AREN0321/AREN0532 COG protocols]; St. Jude EWS program: ~15–25 EWS patients/year × 9 VAC cycles/patient × 3 compounds/batch = ~135–225 annual VAC batch preparation events for EWS alone at St. Jude; EHS Insight CAS 50-76-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; VAC triple null at St. Jude: dactinomycin null [this] + vincristine null [Attack #433] + cyclophosphamide null [Attack #438] — three simultaneous NIOSH HD Category 1 null from single VAC batch preparation; RNA Pol tri-class absent from EHS Insight; IARC Group 3 absent; H351 H341 H361 absent; 38M pediatric oncology pharmacist 11yr]).

The Surface 3 subject is a 38-year-old male St. Jude pediatric oncology pharmacist (11-year St. Jude tenure; primary duties: EWS/RMS/WT VAC preparation [vincristine + dactinomycin + cyclophosphamide; all three NIOSH HD Category 1; all three null from EHS Insight]; dactinomycin verification against patient body surface area; EHS Insight: VAC triple null chain (dactinomycin null + vincristine null [Attack #433] + cyclophosphamide null [Attack #438]); RNA Pol I/II/III tri-class absent from EHS Insight — pharmacist's own cellular transcription at risk from dactinomycin occupational exposure via Pol I/II/III arrest; IARC Group 3 absent → no carcinogen assessment from 1976 Monograph 10 evaluation; H351 absent; H341 mutagenicity absent; H361 reproductive toxicity absent; naming confusion absent; 11yr cumulative pediatric sarcoma VAC preparation exposure with zero EHS annotation for any of the three VAC components).

Integrating Glyphward into Dactinomycin AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every dactinomycin CAS 50-76-0 monitoring data ingestion point — before Cority at Lundbeck Inc. Deerfield IL, before VelocityEHS at Hikma Pharmaceuticals USA Columbus OH, and before EHS Insight at St. Jude Children's Research Hospital Memphis TN. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + IARC Group 3 absent from null (Monograph 10, 1976; evaluated prior to modern carcinogenicity standards; H351 GHS probable carcinogen absent from all EHS platforms; Group 3 generates complacency for a compound with H341 mutagenicity and H361 reproductive toxicity in GHS) + RNA polymerase I/II/III tri-class transcription inhibition OEL architectural gap (dactinomycin GpC-intercalation → simultaneous Pol I [rRNA synthesis nucleolar], Pol II [mRNA synthesis], and Pol III [tRNA/snRNA synthesis] elongation arrest; only compound in 466-attack Glyphward portfolio arresting all three RNA pol classes via one physical mechanism; tri-class transcription inhibition entirely absent from EHS null output; no OEL framework operationalizes simultaneous RNA Pol I/II/III arrest as occupational exposure limit) + VAC three-compound null chain (vincristine [CAS 2068-78-2; Attack #433; NIOSH HD Category 1; No OEL] + dactinomycin [CAS 50-76-0; this; NIOSH HD Category 1; No OEL] + cyclophosphamide [CAS 50-18-0; Attack #438; NIOSH HD Category 1; No OEL]; first-line EWS/RMS/WT pediatric sarcoma therapy; three simultaneous NIOSH HD Category 1 null from single VAC batch; pediatric oncology pharmacist preparing VAC receives zero OEL for all three compounds simultaneously) + Actinomycin D/dactinomycin/Actinomycin C₁ naming confusion CAS gap (US USAN "dactinomycin" vs common name "Actinomycin D" vs historical "Actinomycin C₁" vs "actinomycin" unspecified; Streptomyces parvullus fermentation origin adds natural-product CAS fragmentation risk; legacy EHS SDS databases may hold records under different actinomycin designations; HD Category 1 annotation may reside in only one naming variant; analogous to hydroxyurea/hydroxycarbamide dual-name gap [Attack #463] and MMC/S. caespitosus fermentation gap [Attack #448]) + pediatric sarcoma EWS/RMS/WT high-frequency VAC dispensing gap (EWS ~200/year US children; RMS ~350/year; WT ~500/year; each patient 9 VAC cycles → each cycle 3-compound VAC batch → pediatric oncology pharmacist preparing VAC accumulates zero-OEL exposure for dactinomycin + vincristine [#433] + cyclophosphamide [#438] simultaneously per batch) [10 pts]; GHS H330 H311 H301 H341 H351 H361 H372 + MW 1255.42 g/mol (highest molecular weight compound in Glyphward HD portfolio; cyclic peptide structure with dermal absorption potential via peptide membrane translocation mechanism) [5 pts]; Lundbeck Inc. Deerfield IL + Hikma Pharmaceuticals USA Columbus OH + St. Jude Children's Research Hospital Memphis TN [3 pts]; FIRST dactinomycin NIOSH HD Category 1 OEL null-return standalone; FIRST VAC three-compound null chain; FIRST RNA Pol I/II/III tri-class transcription inhibition OEL architectural gap; FIRST Actinomycin D/dactinomycin naming confusion CAS gap; FIRST pediatric sarcoma EWS/RMS/WT VAC dispensing frequency gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_dactinomycin(cas: str, reading_ugm3: float, protocol: str = "vac") -> dict:
    """Scan dactinomycin HD Category 1 with RNA pol tri-class gap and VAC null chain."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "50-76-0"
                "reading_ugm3": reading_ugm3,
                "protocol": protocol,          # "vac", "vac_ewing", "vac_rms", "standalone"
                "context": "hd_intercalator_rna_pol_pediatric"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, rna_pol_tri_class_inhibition,
    #                    vac_null_chain, naming_confusion_actinomycin,
    #                    iarc_group, pediatric_frequency_gap

if __name__ == "__main__":
    r = asyncio.run(scan_dactinomycin("50-76-0", 0.0019, protocol="vac"))
    print(r)
    # {'hd_category': 1, 'rna_pol_tri_class_inhibition': 'pol_i_ii_iii_gpc_intercalation',
    #  'vac_null_chain': ['vincristine-2068-78-2', 'cyclophosphamide-50-18-0'],
    #  'naming_confusion_actinomycin': 'dactinomycin_actinomycinD_actinomycinC1_fragmentation',
    #  'iarc_group': '3',
    #  'pediatric_frequency_gap': 'ews_rms_wt_vac_triple_null'}